Live Breaking News & Updates on Chinese Demodex

Stay updated with breaking news from Chinese demodex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society of Cardiology Congress 2023 with simultaneous publication in JAMA Cardiology Topline data announced from Phase 3 trial of TP-03 in Chinese Demodex blepharitis patientsCash, cash equivalents and marketable securities of $252.2 million as of September 30, 2023Strategic review ongo ....

United States , Hong Kong , Katherine Smith , Bristol Myers Squibb , Yizhe Wang , European Society Of Cardiology Congress , European Society Of Cardiology , European Society For Medical Oncology , Clinical Development Updates , Myokardia Inc , Exchange Commission , Research Development Expenses , European Society , Cardiology Congress , Chinese Demodex , Chief Executive Officer , Business Highlights , Mainland China , Medical Oncology , Greater China , Annual Report , Months Ended September , Clinical Development , European Society Of Cardiology , Clinical Trial , Mainland China ,

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointData from EXPLORER-CN trial to be presented in an oral late-breaking science session at European Society of Cardiology Congress 2023Cash, cash equivalents and marketable securities of $267.3 million with runway into the first half of 2025 ....

Hong Kong , United States , Macau Special Administrative Region , Macau General , Asia Pacific , Josh Xu , Katherine Smith , Elizabeth Anderson , Pascal Qian , Yizhe Wang , Clinical Development Updates , China National Medical Products Administration , European Society Of Cardiology , Research Development Expenses , European Society Of Cardiology Congress , Chinese Cardiovascular Association , Exchange Commission , Tarsus Pharmaceuticals , Vp Communications , York Heart Association Class , Company Phase , Drug Administration , European Society Of Medical Oncology , Mavacamten New Drug Application , European Society , Cardiology Congress ,